Study S001921
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity
Registration
Registered primary outcomes
- Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events) [Up to 5 Years]
Linked records (4)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0016508 | Cardioprotective effects of a 'twincretin' drug tirzepatide in heart failure following myocardial infarction. Shang R, Cardiovascular research | 2025 | Other trial | PMID 39902650DOI | cites ClinicalTrials.gov:NCT05556512 |
| R0016928 | Weekly Journal Scan: long-term effects of tirzepatide for diabetes prevention in persons with obesity and prediabetes. Pedicino D, European heart journal | 2025 | Other trial | PMID 40249363DOI | cites ClinicalTrials.gov:NCT05556512 |
| R0032683 | 144-OR: Sustained Weight Reduction by Thresholds in Adults with Obesity and Prediabetes Treated with Tirzepatide over 176 Weeks (SURMOUNT-1) Jamy D. Ard, Diabetes | 2025 | Randomized trial | DOI | cites ClinicalTrials.gov:NCT05556512 |
| R0020412 | Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes. Mather KJ, Diabetes, obesity & metabolism | 2024 | Randomized trial | PMID 37989596DOI | cites ClinicalTrials.gov:NCT05556512 |